Press Releases

press releases

Date Title
Nov 11, 2023 Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
Nov 07, 2023 Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Nov 02, 2023 Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Oct 26, 2023 Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
Oct 25, 2023 Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Oct 25, 2023 Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Oct 19, 2023 Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
Oct 09, 2023 Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Oct 06, 2023 Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
Sep 13, 2023 Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

For Media Inquiries, please contact:

Christine Lindenboom

SVP, Investor Relations & Corporate Communications 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

VP, Investor Relations & Corporate Communications 617-551-8276


Essential assets and documents related to Alnylam

Looking for specific information that isn't listed above?